Pathophysiology and therapy of pruritus in allergic and atopic diseases

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 65, Issue 7, 2010, Pages 805-821

  Buddenkotte, J ^a   Steinhoff, M ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atopic dermatitis; Itch; Nerve; Pathophysiology; Pruritus; Therapy

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; ACETYLCHOLINE; ANTIHISTAMINIC AGENT; CANNABINOID RECEPTOR; CAPSAICIN; CETIRIZINE; CYCLOSPORIN A; CYTOKINE; DOXEPIN; GABAPENTIN; GAMMA INTERFERON; GLUCOCORTICOID; HISTAMINE; IMMUNOGLOBULIN; KAPPA OPIATE RECEPTOR AGONIST; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MU OPIATE RECEPTOR ANTAGONIST; NALFURAFINE; NALOXONE; NEUROPEPTIDE; NEUROTROPHIN 4; OPIATE RECEPTOR; PIMECROLIMUS; PLACEBO; PREGABALIN; TACROLIMUS; THROMBOCYTE ACTIVATING FACTOR; TRYPTASE; VANILLOID RECEPTOR;

ATOPIC DERMATITIS; BASOPHIL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DORSAL ROOT; EOSINOPHIL; HUMAN; INFLAMMATORY CELL; NERVE CONDUCTION; NERVE ENDING; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; REVIEW; SCRATCHING; SKIN DISEASE; SKIN MANIFESTATION; SPINAL CORD; STRESS; SWEATING; COMPLICATION; DERMATITIS, ATOPIC; HYPERSENSITIVITY; INNERVATION; SKIN;

DERMATITIS, ATOPIC; HUMANS; HYPERSENSITIVITY; PRURITUS; SKIN;

EID: 77953113044     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2010.01995.x     Document Type: Review

References (260)

1. Rothman S. Physiology of itching. Physiol Rev 1941 21 : 357 381.
2. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980 92 : 44 47.
3. Koblenzer CS. Itching and the atopic skin. J Allergy Clin Immunol 1999 104 (3 Pt 2 S109 S113.
4. von Frey M. [On the physiology of pruritus]. Arch Neerland Physiol 1922 7 : 142 145.
5. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjork HE. Specific C-receptors for itch in human skin. J Neurosci 1997 17 : 8003 8008.
6. Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001 4 : 72 77.
7. Paus R, Schmelz M, Biro T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006 116 : 1174 1186.
8. Handwerker HO, Schmelz M. Pain: itch without pain-a labeled line for itch sensation? Nat Rev Neurol 2009 5 : 640 641.
9. Carstens E. Responses of rat spinal dorsal horn neurons to intracutaneous microinjection of histamine, capsaicin, and other irritants. J Neurophysiol 1997 77 : 2499 2514.
10. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007 448 : 700 703.
11. Carstens EE, Carstens MI, Simons CT, Jinks SL. Dorsal horn neurons expressing NK-1 receptors mediate scratching in rats. Neuroreport 2010 21 : 303 308.
12. Mantyh PW, Rogers SD, Honore P, Allen BJ, Ghilardi JR, Li J et al. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science 1997 278 : 275 279.
13. Nichols ML, Allen BJ, Rogers SD, Ghilardi JR, Honore P, Luger NM et al. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 1999 286 : 1558 1561.
14. Hsieh JC, Hagermark O, Stahle-Backdahl M, Ericson K, Eriksson L, Stone-Elander S et al. Urge to scratch represented in the human cerebral cortex during itch. J Neurophysiol 1994 72 : 3004 3008.
15. 2O positron emission tomography studies. Pain 2001 92 : 295 305.
16. Mochizuki H, Tashiro M, Kano M, Sakurada Y, Itoh M, Yanai K. Imaging of central itch modulation in the human brain using positron emission tomography. Pain 2003 105 : 339 346.
17. Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF. Cellular basis of itch sensation. Science 2009 325 : 1531 1534.
18. Lewis T. The blood vessels of the human skin and their responses.
19. Lewis T, Grant RT, Marvin HM. Vascular reactions of the skin to injury. Heart 1929 14 : 139 160.
20. Williams DH. Skin temperature reaction to histamine in atopic dermatitis (disseminated neurodermatitis). J Invest Dermatol 1938 1 : 119 129.
21. Johnson HH, Jr., Deoreo GA, Lascheid WP, Mitchell F. Skin histamine levels in chronic atopic dermatitis. J Invest Dermatol 1960 34 : 237 238.
22. Juhlin L. Localization and content of histamine in normal and diseased skin. Acta Derm Venereol 1967 47 : 383 391.
23. Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev 1990 42 : 45 83.
24. Turner AJ, Hick PE. Inhibition of aldehyde reductase by acidic metabolites of the biogenic amines. Biochem Pharmacol 1975 24 : 1731 1733.
25. Malaviya R, Morrison AR, Pentland AP. Histamine in human epidermal cells is induced by ultraviolet light injury. J Invest Dermatol 1996 106 : 785 789.
26. Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev 2008 88 : 1183 1241.
27. Stander S, Weisshaar E, Luger TA. Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol 2008 17 : 161 169.
28. Barthel W, Markwardt F. Aggregation of blood platelets by adrenaline and its uptake. Biochem Pharmacol 1975 24 : 1903 1904.
29. Hagermark O, Strandberg K, Gronneberg R. Effects of histamine receptor antagonists on histamine-induced responses in human skin. Acta Derm Venereol 1979 59 : 297 300.
30. Sugimoto Y, Iba Y, Nakamura Y, Kayasuga R, Kamei C. Pruritus-associated response mediated by cutaneous histamine H3 receptors. Clin Exp Allergy 2004 34 : 456 459.
31. Ruzicka T, Gluck S. Cutaneous histamine levels and histamine releasability from the skin in atopic dermatitis and hyper-IgE-syndrome. Arch Dermatol Res 1983 275 : 41 44.
32. Hanifin JM. The role of antihistamines in atopic dermatitis. J Allergy Clin Immunol 1990 86 (4 Pt 2 666 669.
33. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999 135 : 1522 1525.
34. Munday J, Bloomfield R, Goldman M, Robey H, Kitowska GJ, Gwiezdziski Z et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology 2002 205 : 40 45.
35. Rukwied R, Lischetzki G, McGlone F, Heyer G, Schmelz M. Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients: a dermal microdialysis study. Br J Dermatol 2000 142 : 1114 1120.
36. Heyer G, Hornstein OP, Handwerker HO. Skin reactions and itch sensation induced by epicutaneous histamine application in atopic dermatitis and controls. J Invest Dermatol 1989 93 : 492 496.
37. Heyer G, Koppert W, Martus P, Handwerker HO. Histamine and cutaneous nociception: histamine-induced responses in patients with atopic eczema, psoriasis and urticaria. Acta Derm Venereol 1998 78 : 123 126.
38. Heyer GR, Hornstein OP. Recent studies of cutaneous nociception in atopic and non-atopic subjects. J Dermatol 1999 26 : 77 86.
39. Uehara M. Reduced histamine reaction in atopic dermatitis. Arch Dermatol 1982 118 : 244 245.
40. Heyer G, Hornstein OP, Handwerker HO. Reactions to intradermally injected substance P and topically applied mustard oil in atopic dermatitis patients. Acta Derm Venereol 1991 71 : 291 295.
41. Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 2004 142 : 374 380.
42. Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev 2006 86 : 1309 1379.
43. Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H(4) receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Invest Dermatol 2010 130 : 1023 1033.
44. Heyer G, Ulmer FJ, Schmitz J, Handwerker HO. Histamine-induced itch and alloknesis (itchy skin) in atopic eczema patients and controls. Acta Derm Venereol 1995 75 : 348 352.
45. Rukwied R, Heyer G. Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and acetylcholine in atopic eczema patients and healthy controls. Arch Dermatol Res 1998 290 : 198 204.
46. Wahlgren CF. Pathophysiology of itching in urticaria and atopic dermatitis. Allergy 1992 47 (2 Pt 1 65 75.
47. Wahlgren CF. Measurement of itch. Semin Dermatol 1995 14 : 277 284.
48. Ansel JC, Kaynard AH, Armstrong CA, Olerud J, Bunnett N, Payan D. Skin-nervous system interactions. J Invest Dermatol 1996 106 : 198 204.
49. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp Dermatol 1998 7 : 81 96.
50. Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev 2000 21 : 457 487.
51. Pincelli C, Fantini F, Massimi P, Giannetti A. Neuropeptide Y-like immunoreactivity in Langerhans cells from patients with atopic dermatitis. Int J Neurosci 1990 51 : 219 220.
52. Pincelli C, Fantini F, Massimi P, Girolomoni G, Seidenari S, Giannetti A. Neuropeptides in skin from patients with atopic dermatitis: an immunohistochemical study. Br J Dermatol 1990 122 : 745 750.
53. Tobin D, Nabarro G, Baart de la Faille H, van Vloten WA, van der Putte SC, Schuurman HJ. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992 90 (4 Pt 1 613 622.
54. Anand P, Springall DR, Blank MA, Sellu D, Polak JM, Bloom SR. Neuropeptides in skin disease: increased VIP in eczema and psoriasis but not axillary hyperhidrosis. Br J Dermatol 1991 124 : 547 549.
55. Fantini F, Pincelli C, Romualdi P, Donatini A, Giannetti A. Substance P levels are decreased in lesional skin of atopic dermatitis. Exp Dermatol 1992 1 : 127 128.
56. Pincelli C, Fantini F, Romualdi P, Lesa G, Giannetti A. Skin levels of vasoactive intestinal polypeptide in atopic dermatitis. Arch Dermatol Res 1991 283 : 230 232.
57. Andoh T, Nagasawa T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther 1998 286 : 1140 1145.
58. Scholzen TE, Steinhoff M, Bonaccorsi P, Klein R, Amadesi S, Geppetti P et al. Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis. J Immunol 2001 166 : 1285 1291.
59. Stellwagen E, Babul J. Stabilization of the globular structure of ferricytochrome c by chloride in acidic solvents. Biochemistry 1975 14 : 5135 5140.
60. Thomsen JS, Sonne M, Benfeldt E, Jensen SB, Serup J, Menne T. Experimental itch in sodium lauryl sulphate-inflamed and normal skin in humans: a randomized, double-blind, placebo-controlled study of histamine and other inducers of itch. Br J Dermatol 2002 146 : 792 800.
61. Ohmura T, Hayashi T, Satoh Y, Konomi A, Jung B, Satoh H. Involvement of substance P in scratching behaviour in an atopic dermatitis model. Eur J Pharmacol 2004 491 : 191 194.
62. Grando SA, Kist DA, Qi M, Dahl MV. Human keratinocytes synthesize, secrete, and degrade acetylcholine. J Invest Dermatol 1993 101 : 32 36.
63. Grando SA, Zelickson BD, Kist DA, Weinshenker D, Bigliardi PL, Wendelschafer-Crabb G et al. Keratinocyte muscarinic acetylcholine receptors: immunolocalization and partial characterization. J Invest Dermatol 1995 104 : 95 100.
64. Kurzen H, Schallreuter KU. Novel aspects in cutaneous biology of acetylcholine synthesis and acetylcholine receptors. Exp Dermatol 2004 13 (Suppl. 4 27 30.
65. Miyamoto T, Nojima H, Kuraishi Y. Intradermal cholinergic agonists induce itch-associated response via M3 muscarinic acetylcholine receptors in mice. Jpn J Pharmacol 2002 88 : 351 354.
66. Scott A. Acetylcholine in normal and diseased skin. Br J Dermatol 1962 74 : 317 322.
67. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO. Chemical response pattern of different classes of C-nociceptors to pruritogens and algogens. J Neurophysiol 2003 89 : 2441 2448.
68. Heyer G, Vogelgsang M, Hornstein OP. Acetylcholine is an inducer of itching in patients with atopic eczema. J Dermatol 1997 24 : 621 625. (Pubitemid 27488399)
69. Vogelsang M, Heyer G, Hornstein OP. Acetylcholine induces different cutaneous sensations in atopic and non-atopic subjects. Acta Derm Venereol 1995 75 : 434 436.
70. Ikoma A, Fartasch M, Heyer G, Miyachi Y, Handwerker H, Schmelz M. Painful stimuli evoke itch in patients with chronic pruritus: central sensitization for itch. Neurology 2004 62 : 212 217.
71. Ikoma A, Rukwied R, Stander S, Steinhoff M, Miyachi Y, Schmelz M. Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol 2003 139 : 1455 1458.
72. Shelley WB, Arthur RP. The neurohistology and neurophysiology of the itch sensation in man. AMA Arch Derm 1957 76 : 296 323.
73. Bernstein JE. Capsaicin in dermatologic disease. Semin Dermatol 1988 7 : 304 309.
74. Brickford RG. Experiments relating to the itch sensation, its peripheral mechanism and central pathway. Clin Sci 1938 3 : 377 386.
75. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000 6 : 151 158.
76. Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003 23 : 6176 6180.
77. Liu Q, Tang Z, Surdenikova L, Kim S, Patel KN, Kim A et al. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 2009 139 : 1353 1365.
78. Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001 106 : 619 632.
79. Zylka MJ, Dong X, Southwell AL, Anderson DJ. Atypical expansion in mice of the sensory neuron-specific Mrg G protein-coupled receptor family. Proc Natl Acad Sci USA 2003 100 : 10043 10048.
80. Lembo PM, Grazzini E, Groblewski T, O'Donnell D, Roy MO, Zhang J et al. Proenkephalin A gene products activate a new family of sensory neuron - specific GPCRs. Nat Neurosci 2002 5 : 201 209.
81. Bandell M, Patapoutian A. Itching for insight. Cell 2009 139 : 1224 1226.
82. Clapham DE. TRP channels as cellular sensors. Nature 2003 426 : 517 524.
83. Chuang HH, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001 411 : 957 962.
84. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci USA 2000 97 : 6155 6160.
85. Mohapatra DP, Nau C. Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J Biol Chem 2003 278 : 50080 50090.
86. Shin J, Cho H, Hwang SW, Jung J, Shin CY, Lee SY et al. Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc Natl Acad Sci USA 2002 99 : 10150 10155.
87. Di Marzo V, Blumberg PM, Szallasi A. Endovanilloid signaling in pain. Curr Opin Neurobiol 2002 12 : 372 379.
88. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001 24 : 487 517.
89. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997 389 : 816 824.
90. Stander S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001 44 : 471 478.
91. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC et al. Itch: scratching more than the surface. QJM 2003 96 : 7 26.
92. Yosipovitch G, Greaves MW, Schmelz M Itch. Lancet 2003 361 : 690 694.
93. Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol 2002 11 : 12 24.
94. Senba E, Katanosaka K, Yajima H, Mizumura K. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res 2004 50 : 257 262.
95. Stander S, Luger TA. [Antipruritic effects of pimecrolimus and tacrolimus]. Hautarzt 2003 54 : 413 417.
96. Nagy I, Santha P, Jancso G, Urban L. The role of the vanilloid (capsaicin) receptor (TRPV1) in physiology and pathology. Eur J Pharmacol 2004 500 : 351 369.
97. Szallasi A. Small molecule vanilloid TRPV1 receptor antagonists approaching drug status: can they live up to the expectations? Naunyn Schmiedebergs Arch Pharmacol 2006 373 : 273 286.
98. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999 51 : 159 212.
99. Bodo E, Kovacs I, Telek A, Varga A, Paus R, Kovacs L et al. Vanilloid receptor-1 (VR1) is widely expressed on various epithelial and mesenchymal cell types of human skin. J Invest Dermatol 2004 123 : 410 413.
100. Denda M, Fuziwara S, Inoue K, Denda S, Akamatsu H, Tomitaka A et al. Immunoreactivity of VR1 on epidermal keratinocyte of human skin. Biochem Biophys Res Commun 2001 285 : 1250 1252.
101. Inoue K, Koizumi S, Fuziwara S, Denda S, Inoue K, Denda M. Functional vanilloid receptors in cultured normal human epidermal keratinocytes. Biochem Biophys Res Commun 2002 291 : 124 129.
102. Stander S, Moormann C, Schumacher M, Buddenkotte J, Artuc M, Shpacovitch V et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 2004 13 : 129 139.
103. Bodo E, Biro T, Telek A, Czifra G, Griger Z, Toth BI et al. A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol 2005 166 : 985 998.
104. Southall MD, Li T, Gharibova LS, Pei Y, Nicol GD, Travers JB. Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J Pharmacol Exp Ther 2003 304 : 217 222.
105. Pecze L, Szabo K, Szell M, Josvay K, Kaszas K, Kusz E et al. Human keratinocytes are vanilloid resistant. PLoS ONE 2008 3 : e3419.
106. Nilius B, Owsianik G, Voets T, Peters JA. Transient receptor potential cation channels in disease. Physiol Rev 2007 87 : 165 217.
107. Yoshioka T, Imura K, Asakawa M, Suzuki M, Oshima I, Hirasawa T et al. Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice. J Invest Dermatol 2009 129 : 714 722.
108. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005 5 : 400 411.
109. Akerman S, Kaube H, Goadsby PJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol 2004 142 : 1354 1360.
110. van der Stelt M, Trevisani M, Vellani V, De Petrocellis L, Schiano Moriello A, Campi B et al. Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J 2005 24 : 3026 3037.
111. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003 52 : 238 245.
112. Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 2003 278 : 33896 33903.
113. Stander S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005 38 : 177 188.
114. Kemeny L. Comparative study of S236 cream and hydrocortisone 1% in patients with atopic dermatitis (Abstract). J Am Acad Dermatol 2006 52 (suppl. 68.
115. Ward L, Wright E, McMahon SB. A comparison of the effects of noxious and innocuous counterstimuli on experimentally induced itch and pain. Pain 1996 64 : 129 138.
116. Nilsson HJ, Levinsson A, Schouenborg J. Cutaneous field stimulation (CFS): a new powerful method to combat itch. Pain 1997 71 : 49 55.
117. Yosipovitch G, Fast K, Bernhard JD. Noxious heat and scratching decrease histamine-induced itch and skin blood flow. J Invest Dermatol 2005 125 : 1268 1272.
118. Atanassoff PG, Brull SJ, Zhang J, Greenquist K, Silverman DG, Lamotte RH. Enhancement of experimental pruritus and mechanically evoked dysesthesiae with local anesthesia. Somatosens Mot Res 1999 16 : 291 298. (Pubitemid 30006504)
119. Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979 115 : 1366 1367.
120. Fjellner B, Hagermark O. Potentiation of histamine-induced itch and flare responses in human skin by the enkephalin analogue FK-33-824, beta-endorphin and morphine. Arch Dermatol Res 1982 274 : 29 37.
121. Fjellner B, Hagermark O. The influence of the opiate antagonist naloxone on experimental pruritus. Acta Derm Venereol 1984 64 : 73 75.
122. Hagermark O. Peripheral and central mediators of itch. Skin Pharmacol 1992 5 : 1 8.
123. Ko MC, Naughton NN. An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology 2000 92 : 795 805.
124. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995 332 : 1685 1690.
125. Summerfield JA. Pain, itch and endorphins. Br J Dermatol 1981 105 : 725 726.
126. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995 123 : 161 167.
127. Bernstein JE, Grinzi RA. Butorphanol-induced pruritus antagonized by naloxone. J Am Acad Dermatol 1981 5 : 227 228.
128. Brune A, Metze D, Luger TA, Stander S. [Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients]. Hautarzt 2004 55 : 1130 1136.
129. Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999 41 : 533 539.
130. Metze D, Reimann S, Luger TA. Effective treatment of pruritus with naltrexone, an orally active opiate antagonist. Ann NY Acad Sci 1999 885 : 430 432.
131. Penning JP, Samson B, Baxter AD. Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine. Can J Anaesth 1988 35 : 599 604.
132. Summerfield JA. Naloxone modulates the perception of itch in man. Br J Clin Pharmacol 1980 10 : 180 183.
133. Cohen SE, Ratner EF, Kreitzman TR, Archer JH, Mignano LR. Nalbuphine is better than naloxone for treatment of side effects after epidural morphine. Anesth Analg 1992 75 : 747 752.
134. Rawal N, Schott U, Dahlstrom B, Inturrisi CE, Tandon B, Sjostrand U et al. Influence of naloxone infusion on analgesia and respiratory depression following epidural morphine. Anesthesiology 1986 64 : 194 201.
135. Rebel A, Sloan P, Andrykowski M. Postoperative analgesia after radical prostatectomy with high-dose intrathecal morphine and intravenous naloxone: a retrospective review. J Opioid Manag 2009 5 : 331 339.
136. Ko MC, Husbands SM. Effects of atypical kappa opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 2009 328 : 193 200.
137. Braudeau C, Bouchet D, Tesson L, Iyer S, Remy S, Buelow R et al. Induction of long-term cardiac allograft survival by heme oxygenase-1 gene transfer. Gene Ther 2004 11 : 701 710.
138. Heishman SJ, Stitzer ML, Bigelow GE, Liebson IA. Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure. J Pharmacol Exp Ther 1989 248 : 127 134.
139. Kishioka S, Paronis CA, Lewis JW, Woods JH. Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys. Eur J Pharmacol 2000 391 : 289 297.
140. Ko MC, Lee H, Song MS, Sobczyk-Kojiro K, Mosberg HI, Kishioka S et al. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther 2003 305 : 173 179.
141. Wikstrom B, Gellert R, Ladefoged SD, Danda Y, Akai M, Ide K et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005 16 : 3742 3747.
142. Georgala S, Schulpis KH, Papaconstantinou ED, Stratigos J. Raised beta-endorphin serum levels in children with atopic dermatitis and pruritus. J Dermatol Sci 1994 8 : 125 128.
143. Bigliardi-Qi M, Lipp B, Sumanovski LT, Buechner SA, Bigliardi PL. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology 2005 210 : 91 99.
144. Biro T, Ko MC, Bromm B, Wei ET, Bigliardi P, Siebenhaar F et al. How best to fight that nasty itch - from new insights into the neuroimmunological, neuroendocrine, and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 2005 14 : 225 240.
145. van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease. Arch Dermatol 1987 123 : 166 167.
146. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990 70 : 323 329.
147. Cremer B, Heimann A, Dippel E, Czarnetzki BM. Pruritogenic effects of mitogen-stimulated peripheral blood mononuclear cells in atopic eczema. Acta Derm Venereol 1995 75 : 426 428.
148. Darsow U, Scharein E, Bromm B, Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 1997 137 : 415 417.
149. Wahlgren CF, Tengvall Linder M, Hagermark O, Scheynius A. Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res 1995 287 : 572 580.
150. Martin HA. Bradykinin potentiates the chemoresponsiveness of rat cutaneous C-fibre polymodal nociceptors to interleukin-2. Arch Physiol Biochem 1996 104 : 229 238.
151. Sticherling M, Bornscheuer E, Schroder JM, Christophers E. Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin. J Invest Dermatol 1991 96 : 26 30.
152. Kimata H, Lindley I. Detection of plasma interleukin-8 in atopic dermatitis. Arch Dis Child 1994 70 : 119 122.
153. Hatano Y, Katagiri K, Takayasu S. Increased levels in vivo of mRNAs for IL-8 and macrophage inflammatory protein-1 alpha (MIP-1 alpha), but not of RANTES mRNA in peripheral blood mononuclear cells of patients with atopic dermatitis (AD). Clin Exp Immunol 1999 117 : 237 243.
154. Lippert U, Hoer A, Moller A, Ramboer I, Cremer B, Henz BM. Role of antigen-induced cytokine release in atopic pruritus. Int Arch Allergy Immunol 1998 116 : 36 39.
155. Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M, Nakaike S. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2005 516 : 180 181.
156. Kasraie S, Niebuhr M, Werfel T. Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy 2009 DOI:
157. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006 117 : 411 417.
158. Bos JD, Brenninkmeijer EE, Schram ME, Middelkamp-Hup MA, Spuls PI, Smitt JH. Atopic eczema or atopiform dermatitis. Exp Dermatol 2010 DOI:
159. Quesada JR, Gutterman JU, Hersh EM. Clinical and immunological study of beta interferon by intramuscular route in patients with metastatic breast cancer. J Interferon Res 1982 2 : 593 599.
160. de Wolf JT, Hendriks DW, Egger RC, Esselink MT, Halie MR, Vellenga E. Alpha-interferon for intractable pruritus in polycythaemia vera. Lancet 1991 337 : 241.
161. Kolde G, Sunderkotter C, Luger TA. Treatment of urticaria pigmentosa using interferon alpha. Br J Dermatol 1995 133 : 91 94.
162. Silver RT. A new treatment for polycythemia vera: recombinant interferon alfa. Blood 1990 76 : 664 665.
163. Reinhold U, Kukel S, Brzoska J, Kreysel HW. Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 1993 29 : 58 63.
164. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998 134 : 799 804.
165. Reinhold U, Wehrmann W, Kukel S, Kreysel HW. Evidence that defective interferon-gamma production in atopic dermatitis patients is due to intrinsic abnormalities. Clin Exp Immunol 1990 79 : 374 379.
166. Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Dermatol 2000 114 : 1108 1112.
167. Akdis CA, Akdis M, Trautmann A, Blaser K. Immune regulation in atopic dermatitis. Curr Opin Immunol 2000 12 : 641 646.
168. Czarnetzki BM, Csato M. Comparative studies of human eosinophil migration towards platelet-activating factor and leukotriene B4. Int Arch Allergy Appl Immunol 1989 88 : 191 193.
169. Sigal CE, Valone FH, Holtzman MJ, Goetzl EJ. Preferential human eosinophil chemotactic activity of the platelet-activating factor (PAF) 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine (AGEPC). J Clin Immunol 1987 7 : 179 184.
170. Velazquez JR, Lacy P, Moqbel R. Replenishment of RANTES mRNA expression in activated eosinophils from atopic asthmatics. Immunology 2000 99 : 591 599.
171. Weller PF, Lee CW, Foster DW, Corey EJ, Austen KF, Lewis RA. Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. Proc Natl Acad Sci USA 1983 80 : 7626 7630.
172. Yamamoto J, Adachi Y, Onoue Y, Kanegane H, Miyawaki T, Toyoda M et al. CD30 expression on circulating memory CD4+ T cells as a Th2-dominated situation in patients with atopic dermatitis. Allergy 2000 55 : 1011 1018.
173. Lebel B, Venencie PY, Saurat JH, Soubrane C, Paupe J. Anti-IgE induced histamine release from basophils in children with atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980 92 : 57 59.
174. von der Helm D, Ring J, Dorsch W. Comparison of histamine release and prostaglandin E2 production of human basophils in atopic and normal individuals. Arch Dermatol Res 1987 279 : 536 542.
175. Bull HA, Courtney PF, Bunker CB, Rustin MH, Pearce FL, Dowd PM. Basophil mediator release in atopic dermatitis. J Invest Dermatol 1993 100 : 305 309.
176. Jarvikallio A, Naukkarinen A, Harvima IT, Aalto ML, Horsmanheimo M. Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. Br J Dermatol 1997 136 : 871 877.
177. Fjellner B, Hagermark O. Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. Acta Derm Venereol 1985 65 : 409 412.
178. Abeck D, Andersson T, Grosshans E, Jablonska S, Kragballe K, Vahlquist A et al. Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis. Acta Derm Venereol 1997 77 : 449 451.
179. Devillier P, Baccard N, Advenier C. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I: synthesis, receptors and role of leukotrienes in asthma. Pharmacol Res 1999 40 : 3 13.
180. Andoh T, Kuraishi Y. Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. Eur J Pharmacol 1998 353 : 93 96.
181. Miyoshi M, Sakurai T, Kodama S. [Clinical evaluation of urinary leukotriene E4 levels in children with atopic dermatitis]. Arerugi 1999 48 : 1148 1152.
182. Carucci JA, Washenik K, Weinstein A, Shupack J, Cohen DE. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998 134 : 785 786.
183. Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999 83 (6 Pt 1 548 552.
184. Zabawski EJ, Jr., Kahn MA, Gregg LJ. Treatment of atopic dermatitis with zafirlukast. Dermatol Online J 1999 5 : 10.
185. Hanifin JM. Pharmacophysiology of atopic dermatitis. Clin Rev Allergy 1986 4 : 43 65.
186. Morren MA, Przybilla B, Bamelis M, Heykants B, Reynaers A, Degreef H. Atopic dermatitis: triggering factors. J Am Acad Dermatol 1994 31 (3 Pt 1 467 473.
187. Rajka G. Essential aspects of atopic dermatitis.
188. Mihara K, Kuratani K, Matsui T, Nakamura M, Yokota K. Vital role of the itch-scratch response in development of spontaneous dermatitis in NC/Nga mice. Br J Dermatol 2004 151 : 335 345.
189. Werner Y. The water content of the stratum corneum in patients with atopic dermatitis. Measurement with the Corneometer CM 420. Acta Derm Venereol 1986 66 : 281 284.
190. Fartasch M, Diepgen TL. The barrier function in atopic dry skin. Disturbance of membrane-coating granule exocytosis and formation of epidermal lipids? Acta Derm Venereol Suppl (Stockh) 1992 176 : 26 31.
191. Werner Y, Lindberg M, Forslind B. Membrane-coating granules in "dry" non-eczematous skin of patients with atopic dermatitis. A quantitative electron microscopic study. Acta Derm Venereol 1987 67 : 385 390.
192. Hägermark Ö. The pathophysiology of itch. In : Ruzicka T, Przybilla B, Ring J, editors. Handbook of atopic eczema.
193. Wahlgren CF. Itch and atopic dermatitis: an overview. J Dermatol 1999 26
194. Yoshiike T, Aikawa Y, Sindhvananda J, Suto H, Nishimura K, Kawamoto T et al. Skin barrier defect in atopic dermatitis: increased permeability of the stratum corneum using dimethyl sulfoxide and theophylline. J Dermatol Sci 1993 5 : 92 96.
195. Choi EH, Brown BE, Crumrine D, Chang S, Man MQ, Elias PM et al. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J Invest Dermatol 2005 124 : 587 595.
196. Griesemer RD. Emotionally triggered disease in a dermatological practice. Psychatr Ann 1978 8 : 49 56.
197. Niemeier V, Kupfer J, Gieler U. Observations during an itch-inducing lecture. Dermatol Psychosom 2000 1 : 15 18.
198. Fjellner B, Arnetz BB. Psychological predictors of pruritus during mental stress. Acta Derm Venereol 1985 65 : 504 508. (Pubitemid 16204657)
199. Fjellner B, Arnetz BB, Eneroth P, Kallner A. Pruritus during standardized mental stress. Relationship to psychoneuroendocrine and metabolic parameters. Acta Derm Venereol 1985 65 : 199 205.
200. Metze D, Reimann S, Luger T. Juckreiz -Symptom oder Krankheit. In : Plewig G, Przybilla B, editors. Fortschritte der praktischen Dermatologie und Venerologie.
201. Koblenzer CS. Psychocutaneous disease.
202. Gupta MA, Gupta AK, Schork NJ, Ellis CN. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 1994 56 : 36 40.
203. Cormia FE. Experimental histamine pruritus. I. Influence of physical and psychological factors on threshold reactivity. J Invest Dermatol 1952 19 : 21 34.
204. Arnetz BB, Fjellner B, Eneroth P, Kallner A. Endocrine and dermatological concomitants of mental stress. Acta Derm Venereol Suppl (Stockh) 1991 156 : 9 12.
205. Buhk H, Muthny FA. [Psychophysiologic and psychoneuroimmunologic studies in neurodermatitis. Overview and critical evaluation]. Hautarzt 1997 48 : 5 11.
206. Hermanns N, Scholz OB. Kognitive Einflüsse auf einen histamininduzierten Juckreiz und Quaddelbildung bei der atopischen Dermatitis. Verhaltensmod Verhaltensmed 1992 13 : 171 194.
207. Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: a comparison of psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol 1995 63 : 624 635.
208. Shenefelt PD. Hypnosis in dermatology. Arch Dermatol 2000 136 : 393 399.
209. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders. Brain Behav Immun 1999 13 : 225 239.
210. Buske-Kirschbaum A, Gierens A, Hollig H, Hellhammer DH. Stress-induced immunomodulation is altered in patients with atopic dermatitis. J Neuroimmunol 2002 129 : 161 167.
211. Munzel K, Schandry R. [Atopic eczema: psychophysiological reactivity with standardized stressors]. Hautarzt 1990 41 : 606 611.
212. Beltrani VS. The clinical spectrum of atopic dermatitis. J Allergy Clin Immunol 1999 104 (3 Pt 2 S87 S98.
213. Hanifin JM. Basic and clinical aspects of atopic dermatitis. Ann Allergy 1984 52 : 386 395.
214. Rovensky J, Saxl O. Differences in the dynamics of sweat secretion in atopic children. J Invest Dermatol 1964 43 : 171 176.
215. Metze D, Luger T. Nervous system in the skin. In : Freinkel RK, Woodley DT, editors. The biology of the skin.
216. Graham DT, Wolf S. The relation of eczema to attitude and to vascular reactions of the human skin. J Lab Clin Med 1953 42 : 238 254.
217. Bendsoe N, Bjornberg A, Asnes H. Itching from wool fibres in atopic dermatitis. Contact Dermatitis 1987 17 : 21 22.
218. Wahlgren CF, Hagermark O, Bergstrom R. Patients' perception of itch induced by histamine, compound 48/80 and wool fibres in atopic dermatitis. Acta Derm Venereol 1991 71 : 488 494.
219. Ekblom A, Fjellner B, Hansson P. The influence of mechanical vibratory stimulation and transcutaneous electrical nerve stimulation on experimental pruritus induced by histamine. Acta Physiol Scand 1984 122 : 361 367.
220. Fisher AA. Nonallergic "itch" and "prickly" sensation to wool fibers in atopic and nonatopic persons. Cutis 1996 58 : 323 324.
221. Hogan DJ, Dannaker CJ, Maibach HI. Contact dermatitis: prognosis, risk factors, and rehabilitation. Semin Dermatol 1990 9 : 233 246.
222. Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis, and management. J Allergy Clin Immunol 1999 104 (3 Pt 2 S114 S122.
223. Bueller HA, Bernhard JD. Review of pruritus therapy. Dermatol Nurs 1998 10 : 101 107.
224. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin 2010 26 : 633 640.
225. Bikowski J. Case studies assessing a new skin barrier repair cream for the treatment of atopic dermatitis. J Drugs Dermatol 2009 8 : 1037 1041.
226. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 2009 8 : 1106 1111.
227. Vieluf D, Matthias C. Trockene juckende Haut - ihre Behandlung mit einer neuen Polidocanol-Harnstoff-Zubereitung. Z Hautkr 1992 67 : 816 821.
228. Lundeberg T, Bondesson L, Thomas M. Effect of acupuncture on experimentally induced itch. Br J Dermatol 1987 117 : 771 777.
229. van der Schaar WW, Lamberts H. [Scratching for the itch in eczema; a psychodermatologic approach]. Ned Tijdschr Geneeskd 1997 141 : 2049 2051.
230. Melin L, Frederiksen T, Noren P, Swebilius BG. Behavioural treatment of scratching in patients with atopic dermatitis. Br J Dermatol 1986 115 : 467 474.
231. Hornstein OP, Gall K, Salzer B, Rupprecht M. Controlled physical exercise in patients with chronic neurodermitis. Dtsch Z Sportmed 1998 49 : 39 45.
232. Berth-Jones J, Graham-Brown RA. Failure of terfenadine in relieving the pruritus of atopic dermatitis. Br J Dermatol 1989 121 : 635 637.
233. Henz BM, Metzenauer P, O'Keefe E, Zuberbier T. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. Allergy 1998 53 : 180 183.
234. Wahlgren CF, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 1990 122 : 545 551.
235. Doherty V, Sylvester DG, Kennedy CT, Harvey SG, Calthrop JG, Gibson JR. Treatment of itching in atopic eczema with antihistamines with a low sedative profile. BMJ 1989 298 : 96.
236. Hannuksela M, Kalimo K, Lammintausta K, Mattila T, Turjanmaa K, Varjonen E et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy 1993 70 : 127 133.
237. Danarti R, Waskito F, Indrastuti N. Onset and duration of action of topical antihistamine: a study of histamine skin test response. Int J Dermatol 2008 47 : 861 863.
238. Drake LA, Millikan LE. The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group. Arch Dermatol 1995 131 : 1403 1408.
239. Sabroe RA, Kennedy CT, Archer CB. The effects of topical doxepin on responses to histamine, substance P and prostaglandin E2 in human skin. Br J Dermatol 1997 137 : 386 390.
240. Shelley WB, Shelley ED, Talanin NY. Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream. J Am Acad Dermatol 1996 34 : 143 144.
241. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001 44 (Suppl. 1 S28 S38.
242. Jekler J, Larko O. Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: a paired-comparison study. J Am Acad Dermatol 1990 22 : 49 53.
243. Luger T, Van Leent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001 144 : 788 794.
244. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000 4 : 1 191.
245. Aliaga A, Rodriguez M, Armijo M, Bravo J, Avila AL, Mascaro JM et al. Double-blind study of prednicarbate versus fluocortin butyl ester in atopic dermatitis. Int J Dermatol 1996 35 : 131 132.
246. Maloney JM, Morman MR, Stewart DM, Tharp MD, Brown JJ, Rajagopalan R. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. Int J Dermatol 1998 37 : 142 144.
247. Yosipovitch G, Szolar C, Hui XY, Maibach H. High-potency topical corticosteroid rapidly decreases histamine-induced itch but not thermal sensation and pain in human beings. J Am Acad Dermatol 1996 35 : 118 120.
248. Oiso N, Yudate T, Kawara S, Kawada A. Successful treatment of lichen amyloidosus associated with atopic dermatitis using a combination of narrowband ultraviolet B phototherapy, topical corticosteroids and an antihistamine. Clin Exp Dermatol 2009 34 : e833 e836.
249. De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991 71 : 452 454.
250. Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004 151 (Suppl. 70 3 27. (Pubitemid 40023628)
251. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005 330 : 516.
252. Novak N, Kwiek B, Bieber T. The mode of topical immunomodulators in the immunological network of atopic dermatitis. Clin Exp Dermatol 2005 30 : 160 164.
253. Ruer-Mulard M, Aberer W, Gunstone A, Kekki OM, Lopez Estebaranz JL, Vertruyen A et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol 2009 26 : 551 558.
254. Yan AC, Honig PJ, Ming ME, Weber J, Shah KN. The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. Arch Dermatol 2010 146 : 57 62.
255. Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993 28 (2 Pt 1 189 197.
256. Jang IG, Yang JK, Lee HJ, Yi JY, Kim HO, Kim CW et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000 42 : 1033 1040.
257. Gelfand EW, Landwehr LP, Esterl B, Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 1996 104 (Suppl. 1 61 66.
258. Kimata H. High dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child 1994 70 : 335 336.
259. Reimann S, Luger T, Metze D. [Topical administration of capsaicin in dermatology for treatment of itching and pain]. Hautarzt 2000 51 : 164 172.
260. Damann N, Voets T, Nilius B. TRPs in our senses. Curr Biol 2008 18 : R880 R889.